Evaxion Shares Rise After EVX-01 Phase 2 Results Show 89% Target Precision
Evaxion shares rose more than 8% in premarket trading after the biotech reported three-year results from a Phase 2 trial of its experimental personalized melanoma vaccine. EVX-01 triggered an immune response in every trial patient, the report said.